Extension to in-use stability time FARNBOROUGH, England, [23] March, 2020: Flexipharm Austrading, … Continue reading “Flexipharm Austrading announces product update on Arsenic Trioxide Phebra”
17 March 2020, London, Geneva & Jersey – Medicxi, the leading European … Continue reading “Medicxi Bolsters and Expands Team with Senior Industry Leaders”
NeoPhore Limited, a small molecule cancer immuno-oncology company, today announces the appointment … Continue reading “NeoPhore appoints Dr Matthew Baker as Chief Executive Officer”
Supports Vaccinex’s diversification into clinical development of pepinemab for Alzheimer’s disease IXICO … Continue reading “IXICO announces an expanded contract for its imaging services with Vaccinex”
Currently in Phase 2b development for the treatment of life-threatening fungal infections … Continue reading “F2G Receives US FDA Orphan Drug Designation for Olorofim”
Targeting smaller voids in foot and ankle, orthopaedic reconstruction and trauma Keele, … Continue reading “Biocomposites announces U.S. launch of new STIMULAN® Rapid Cure 3cc product”
Amsterdam, The Netherlands, February 26, 2020 – Kiadis Pharma N.V. (“Kiadis” or … Continue reading “Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML with off-the-shelf NK cells from universal donors”
Geneva, Switzerland, 26 February 2020: iOnctura SA., a clinical stage biopharmaceutical company, developing … Continue reading “iOnctura announces first patient dosed in a phase I clinical study of its novel highly selective PI3Kδ inhibitor, IOA-244 for solid tumours”
Cardiff and London UK, February 25, 2020 – TrakCel, a leading software … Continue reading “TrakCel and Ori Biotech sign a collaboration agreement for supply chain orchestration within cell and gene therapy manufacturing”
We will be presenting a scientific poster on enhancing imaging analysis accuracy … Continue reading “IXICO to present AI segmentation research at Huntington’s Disease Therapeutics Conference”
Amsterdam, Netherlands and Hoboken, New Jersey: February 17, 2020: Castor, a health-tech company … Continue reading “Castor provides free access to data capture platform to support non-profit COVID-19 research projects”
CAMBRIDGE, UK and NEW YORK, USA, 10 February 2020 Artios Pharma Limited … Continue reading “Artios Pharma Strengthens Clinical Development Team with Senior Appointments”
Geneva, Switzerland, 4th February 2020: iOnctura SA, a clinical stage biopharmaceutical company, … Continue reading “iOnctura Expands its Clinical Advisory Board”
vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for … Continue reading “vasopharm completes patient enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)”
LONDON, Jan. 28, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) … Continue reading “Verona Pharma to Present at LSX World Congress 2020”
Madrid, January 27th, 2020.- PharmaMar (PHM:MSE) and Bionical Emas, a global specialist … Continue reading “PharmaMar and Bionical Emas launch Expanded Access Program for lurbinectedin in relapsed Small Cell Lung Cancer in the U.S.”
Madrid, January 27th, 2020.- PharmaMar (PHM:MSE) and Bionical Emas, a global specialist … Continue reading “PharmaMar and Bionical Emas launch Expanded Access Program for lurbinectedin in relapsed Small Cell Lung Cancer in the U.S.”
Amsterdam, The Netherlands, January 23, 2020: iOnctura B.V., a clinical stage biopharmaceutical … Continue reading “iOnctura raises EUR 15 million in Series A financing to progress its pipeline into clinical development”
Acquisition of Consumer Healthcare company Easypharm OTC GmbH strengthens position in … Continue reading “European CNS specialist Neuraxpharm strengthens expansion into Austrian market with acquisition of easypharm”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2020 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com